TRF2 acts as a transcriptional regulator in tumor angiogenesis.
We recently showed that telomeric repeat-binding factor 2 (TRF2) regulates gene expression to promote angiogenesis. We found that TRF2 is highly expressed in tumor vessels and transcriptionally activates platelet-derived growth factor receptor β to promote endothelial cell angiogenic properties independently of its function in telomere protection. This work identifies TRF2 as a promising dual target for cancer therapy.
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France.
Mounir
M
El Maï
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France.
Kay-Dietrich
KD
Wagner
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France.|Department of Pathology; Nice, France.
Jean-François
JF
Michiels
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France.|Department of Medical Genetics; CHU; Nice, France.
Eric
E
Gilson
Institut for Research on Cancer and Aging; Nice (IRCAN); University of Nice Sophia-Antipolis; CNRS UMR7284/INSERM U1081; Faculty of Medicine; Nice, France.
Nicole
N
Wagner
Wilms’ tumor suppressor WT1; telomeres; telomeric repeat-binding factor 2 (TRF2); transcriptional regulation; tumor angiogenesis